FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder [MSNBC.com]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: MSNBC.com
The Food and Drug Administrationon FridayPfizerbleeding disorderfirst-ever gene therapyThe agencygreenlithemophilia BrequirementsThe treatment will be available by prescription to eligible patients this quarter, a Pfizer spokesperson told . It has a hefty $3.5 million price tag, before insurance and other rebates, the spokesperson added, making it by far one of the most expensive drugs in the U.S.More than 7,000 people in the U.S. are living with the debilitatingconditionadvocacy groupcertain proteinBeqvez is a one-time treatment designed to enable patients to produce factor IX themselves and prevent and control bleeding. In a late-stage trial, the drug was superior to the often-cumbersomestandard treatment“Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular [factor IX] infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues,” said Dr. Adam Cuker, director of Penn’s Comprehensive and Hem
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer Pauses Gene Therapy Trial for Muscle Disease After Death [BNN Bloomberg (Canada)]BNN Bloomberg
- Pfizer wants the $75 mln left from SAC Capital's insider trading settlement with SEC [Reuters]Reuters
- Pfizer Dividend Yield Pushes Past 6% [Forbes]Forbes
- US Generic Injectables Market Projected to Reach $44.6 Billion by 2032 [Yahoo! Finance]Yahoo! Finance
- Unresectable Hepatocellular Carcinoma: Global Market Forecast at $2.64 Billion by 2028, Dominated by Pfizer, Johnson & Johnson, Roche, Merck & Co, and Bayer [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 5/1/24 - Form 4
- 5/1/24 - Form 4
- 5/1/24 - Form 8-K
- PFE's page on the SEC website